Similar Papers

Paper Title
Journal
Date
Author
Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series
Christina Wong ... Allison Vidimos
Journal of the American Academy of Dermatology | VOL. 82
Christina Wong, et. al.Christina Wong ... Allison Vidimos
21 Feb 2020
An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas
Duy Cong Tran ... Anne Lynn S Chang
Journal of the American Academy of Dermatology | VOL. 78
Duy Cong Tran, et. al.Duy Cong Tran ... Anne Lynn S Chang
23 Nov 2017
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
...
The Lancet Oncology | VOL. 16
, et. al. ...
13 May 2015
Abstract CN06-04: The hedgehog signaling pathway in cancer.
William H Matsui
Molecular Cancer Therapeutics | VOL. 10
William H MatsuiWilliam H Matsui
12 Nov 2011
View more papers

More From: Archives of Dermatology

Paper Title
Journal
Date
Author
Circumscribed Acral Hypokeratosis: Successful Treatment of a Potentially Premalignant Condition
Lara K Butler ... Elizabeth A Kiracofe
Archives of Dermatology | VOL. 148
Lara K Butler, et. al.Lara K Butler ... Elizabeth A Kiracofe
01 Dec 2012
Treatment of Tattoos With a Picosecond Alexandrite Laser
Nazanin Saedi ... Andrei Metelitsa
Archives of Dermatology | VOL. 148
Nazanin Saedi, et. al.Nazanin Saedi ... Andrei Metelitsa
01 Dec 2012
Error in Reported Percentage in: Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
-
Archives of Dermatology | VOL. 148
--
01 Dec 2012
Violaceous and ulcerated plaque following a cesarean.
Hans Peter Bertsch ... Birka Brauns
Archives of Dermatology | VOL. 148
Hans Peter Bertsch, et. al.Hans Peter Bertsch ... Birka Brauns
01 Dec 2012
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.